BRAF Mutation Test Kits with 0.0001% Detection Sensitivity

Cancer diagnostics company Genecast has launched of ADPS BRAF, EGFR, JAK2 mutation test kits with the highest detection sensitivity. Currently available for research use...
Berg will partner with Massachusetts General Hospital and Brigham and Women's Hospital to study potential biomarkers for Alzheimer's and other neurodegenerative disorders from Harvard Biomarker Study biospecimens. [Source: ajcity.net]

Genetic Link between Alzheimer’s and Brain Inflammation Found

Alzheimer’s Disease (AD) is a notorious death valley for drug discovery, with more than 100 candidate drugs having failed in clinical trials so far....
Black doctor using digital display

The Age of Analytics: Sequencing’s New Frontier Is Clinical Interpretation

David FitzPatrick’s typical patient is a toddler with global developmental delay who is small for her age, has epilepsy, and cannot speak or understand...
Unhealthy Liver Anatomy

Gilead Launches Sequencing Spree After Phase III NASH Flop

Gilead Sciences is turning to gene sequencing to refresh its nonalcoholic steatohepatitis (NASH) pipeline. The company is collaborating with Renown Institute for Health Innovation...

Mining the Microbiome: Microbiome startups are proliferating, exploring new markets, and colonizing diverse therapeutic...

It would be hard to find an area of health where the microbiome has not been implicated as a major player. The microbiome is...

FDA Clears iCubate’s iC-GN Assay for Bloodstream Infection and Subsequent Sepsis

Syndromic test developer iCubate has won FDA clearance for its ic-GN Assay, a qualitative, multiplexed, in vitro diagnostic test designed to detect and identify...

Day Zero Diagnostics Awarded Phase I SBIR Grant for Algorithm Development

Day Zero Diagnostics (DZD) said today it has received a Phase I Small Business Innovation Research (SBIR) award from the NIH’s National Institute of...
Schizophrenia

Therapy Targeting Gene Associated with Psychosis Alleviates Symptoms

Treating psychosis by targeting a genetic mutation alleviates symptoms. That’s according to a new, proof-of-principle study that just may pave the way for precision...
NanoView Biosciences has closed on a $10 million Series B financing

GNS Healthcare Closes $23M Series D Finance Round

Artificial intelligence-powered precision medicine company GNS Healthcare has announced a $23 million Series D fundraising round led by Cigna Ventures, a  wholly owned indirect...

Next-Generation Analytics for Cancer Treatment Decision Making

Oncology Analytics announced the release of Oncology Insights, a next-generation analytics software solution that delivers current, relevant, and structured oncology data, supported by expert...
Scroll Up